IVA (Inventiva) Short Interest


IVA Inventiva SA IVA
40 GF Score
Price $3.48
GF Value $0.29
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Inventiva Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

IVA vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Inventiva's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inventiva Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inventiva's Short Interest distribution charts can be found below:

* The bar in red indicates where Inventiva's Short Interest falls into.


IVA
40GF Score
Inventiva SA IVA
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Inventiva (IVA) Overvalued in 2026?

Based on GuruFocus' analysis, Inventiva stock appears to be overvalued. The current stock price of $3.48 is trading 1100% above its estimated GF Value™ of $0.29. GuruFocus considers Inventiva to be Significantly Overvalued.

Key valuation signals for IVA:

  • Short Interest:
  • GF Value™: $0.29 vs. price of $3.48 (1100% above fair value)
  • GF Score™: 40/100 with 7 warning signs

No single metric tells the full story. See the IVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Inventiva Business Description

Address 50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
40GF Score

Get the complete analysis for IVA

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.48
Price
$0.29
GF Value